Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia
Metrics: PDF 806 views | Full Text 1151 views | ?
Renee C. Tschumper1, Tait D. Shanafelt3, Neil E. Kay4 and Diane F. Jelinek2,4
1Department of Immunology, Mayo Clinic, Rochester, MN, USA
2Department of Immunology, Mayo Clinic, Scottsdale, AZ, USA
3Department of Hematology/Oncology, Stanford University, Stanford, CA, USA
4Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA
Diane F. Jelinek, email: email@example.com
Keywords: long non-coding RNA; chronic lymphocytic leukemia; unmutated immunoglobulin heavy chain variable region; progression; early Rai stage
Received: October 27, 2018 Accepted: December 12, 2018 Published: January 01, 2019
Predicting disease progression in chronic lymphocytic leukemia (CLL) remains challenging particularly in patients with Rai Stage 0/I disease that have an unmutated immunoglobulin heavy chain variable region (UM IGHV). Even though patients with UM IGHV have a poor prognosis and generally require earlier treatment, not all UM IGHV patients experience more rapid disease progression with some remaining treatment free for many years. This observation suggests biologic characteristics other than known prognostic factors influence disease progression. Alterations in long non-coding RNA (lncRNA) expression levels have been implicated in diagnosis and prognosis of various cancers, however, their role in disease progression of early Rai stage UM CLL is unknown. Here we use microarray analysis to compare lncRNA and mRNA profiles of Rai 0/I UM IGHV patients who progressed in <2 years relative to patients who had not progressed for >5 years. Over 1,300 lncRNAs and 940 mRNAs were differentially expressed (fold change ≥ 2.0; p-value ≤ 0.05). Of interest, the differentially expressed lncRNAs T204050, NR_002947, and uc.436+, have known associated genes that have been linked to CLL. Thus, our study reveals differentially expressed lncRNAs in progressive early stage CLL requiring therapy versus indolent early Rai stage UM CLL. These lncRNAs have the potential to impact relevant biological processes and pathways that influence clinical outcome in CLL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.